Modern prodrug design for targeted oral drug delivery

Molecules

Volumn 19, Issue 10, 2014, Pages 16489-16505

  Dahan, Arik ^a   Zimmermann, Ellen M ^b   Ben Shabat, Shimon ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Membrane transporters; Molecular biopharmaceutics; Passive active intestinal permeability; Prodrug activation; Targeted prodrug approach

Indexed keywords

CARRIER PROTEIN; PRODRUG;

ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MEMBRANE TRANSPORT PROTEINS; PERMEABILITY; PRODRUGS;

EID: 84911915292     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191016489     Document Type: Article

References (125)

1. Bildstein, L.; Dubernet, C.; Couvreur, P. Prodrug-based intracellular delivery of anticancer agents. Adv. Drug Deliv. Rev. 2011, 63, 3-23.
2. Huttunen, K.M.; Raunio, H.; Rautio, J. Prodrugs-From serendipity to rational design. Pharmacol. Rev. 2011, 63, 750-771.
3. Stella, V.J. Prodrugs: Some thoughts and current issues. J. Pharm. Sci. 2010, 99, 4755-4765.
4. Beaumont, K.; Webster, R.; Gardner, I.; Dack, K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr. Drug Metab. 2003, 4, 461-485.
5. Dahan, A.; Khamis, M.; Agbaria, R.; Karaman, R. Targeted prodrugs in oral drug delivery: The modern molecular biopharmaceutical approach. Expert Opin. Drug Deliv. 2012, 9, 1001-1013.
6. Han, H.K.; Amidon, G.L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000, 2, 48-58.
7. Sai, Y.; Tsuji, A. Transporter-mediated drug delivery: Recent progress and experimental approaches. Drug Discov. Today 2004, 9, 712-720.
8. Amidon, G.L.; Leesman, G.D.; Elliott, R.L. Improving intestinal absorption of water-insoluble compounds: A membrane metabolism strategy. J. Pharm. Sci. 1980, 69, 1363-1368.
9. Fleisher, D.; Bong, R.; Stewart, B.H. Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev. 1996, 19, 115-130.
10. Stella, V.J.; Nti-Addae, K.W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 2007, 59, 677-694.
11. Bernard, T. Prodrugs: Bridging pharmacodynamic/pharmacokinetic gaps. Curr. Opin. Chem. Biol. 2009, 13, 338-344.
12. Dahan, A.; Duvdevani, R.; Dvir, E.; Elmann, A.; Hoffman, A. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in vitro evaluation of an indomethacin-Lecithin conjugate. J. Control. Release 2007, 119, 86-93.
13. Dahan, A.; Duvdevani, R.; Shapiro, I.; Elmann, A.; Finkelstein, E.; Hoffman, A. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid cgnjugate following oral administration. J. Control. Release 2008, 126, 1-9.
14. Ettmayer, P.; Amidon, G.L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
15. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov. 2008, 7, 255-270.
16. Zawilska, J.; Wojcieszak, J.; Olejniczak, A. Prodrugs: A challenge for the drug development. Pharmacol. Rep. 2013, 65, 1-14.
17. Serafin, A.; Stańczak, A. Different concepts of drug delivery in disease entities. Mini Rev. Med. Chem. 2009, 9, 481-497.
18. Perez, C.; Daniel, K.B.; Cohen, S.M. Evaluating prodrug strategies for esterase-triggered release of alcohols. ChemMedChem 2013, 8, 1662-1667.
19. Horst, H.; Höltje, W.; Dennis, M.; Coert, A.; Geelen, J.; Voigt, K. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr. 1976, 54, 875-879.
20. Dahan, A.; Hoffman, A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 2005, 24, 381-388.
21. Dahan, A.; Hoffman, A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm. Res. 2006, 23, 2165-2174.
22. Dahan, A.; Mendelman, A.; Amsili, S.; Ezov, N.; Hoffman, A. The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: Comparison between anesthetized and freely moving conscious rat models. Eur. J. Pharm. Sci. 2007, 32, 367-374.
23. Shackleford, D.M.; Faassen, W.A.; Houwing, N.; Lass, H.; Edwards, G.A.; Porter, C.J.H.; Charman, W.N. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J. Pharm. Exp. Ther. 2003, 306, 925-933.
24. -1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: Results of a comparative study. Br. J. Dermatol. 2001, 144, 495-499.
25. Ben-Shabat, S.; Benisty, R.; Wormser, U.; Sintov, A.C. Vitamin D3-based conjugates for topical treatment of psoriasis: Synthesis, antiproliferative activity, and cutaneous penetration studies. Pharm. Res. 2005, 22, 50-57.
26. Sintov, A.C.; Yarmolinsky, L.; Dahan, A.; Ben-Shabat, S. Pharmacological effects of vitamin D and its analogs: Recent developments. Drug Discov. Today 2014, in press.
27. Upadhyay, R.K. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed. Res. Int. 2014, 2014, doi:10.1155/2014/869269.
28. Zhao, Y.; Qu, B.; Wu, X.; Li, X.; Liu, Q.; Jin, X.; Guo, L.; Hai, L.; Wu, Y. Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with "lock-in" function. Eur. J. Med. Chem. 2014, 82, 314-323.
29. Majumdar, S.; Duvvuri, S.; Mitra, A.K. Membrane transporter/receptor-targeted prodrug design: Strategies for human and veterinary drug development. Adv. Drug Deliv. Rev. 2004, 56, 1437-1452.
30. Dahan, A.; Amidon, G.L.; Zimmermann, E.M. Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update. Expert Rev. Clin. Immunol. 2010, 6, 543-550.
31. Sabit, H.; Dahan, A.; Sun, J.; Provoda, C.J.; Lee, K.-D.; Hilfinger, J.H.; Amidon, G.L. Cytomegalovirus protease targeted prodrug development. Mol. Pharm. 2013, 10, 1417-1424.
32. Wolk, O.; Epstein, S.; Ioffe-Dahan, V.; Ben-Shabat, S.; Dahan, A. New targeting strategies in drug therapy of inflammatory bowel disease: Mechanistic approaches and opportunities. Expert Opin. Drug Deliv. 2013, 10, 1275-1286.
33. Kato, K.; Shirasaka, Y.; Kuraoka, E.; Kikuchi, A.; Iguchi, M.; Suzuki, H.; Shibasaki, S.; Kurosawa, T.; Tamai, I. Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: Involvement of human OATP family in apical membrane transport. Mol. Pharm. 2010, 7, 1747-1756.
34. Tamai, I. Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Deliv. Rev. 2012, 64, 508-514.
35. Jonker, J.W.; Schinkel, A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 2004, 308, 2-9.
36. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 2007, 24, 1227-1251.
37. Balakrishnan, A.; Polli, J.E. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): A potential prodrug target. Mol. Pharm. 2006, 3, 223-230.
38. Kolhatkar, V.; Polli, J.E. Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur. J. Pharm. Sci. 2012, 46, 86-99.
39. Zheng, X.; Polli, J.E. Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. Int. J. Pharm. 2010, 396, 111-118.
40. Cao, X.; Gibbs, S.; Fang, L.; Miller, H.; Landowski, C.; Shin, H.-C.; Lennernas, H.; Zhong, Y.; Amidon, G.; Yu, L.; et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 2006, 23, 1675-1686.
41. Tsuji, A. Tissue selective drug delivery utilizing carrier-mediated transport systems. J. Control. Release 1999, 62, 239-244.
42. Varma, M.; Ambler, C.; Ullah, M.; Rotter, C.; Sun, H.; Litchfield, J.; Fenner, K.; El-Kattan, A. Targeting intestinal transporters for optimizing oral drug absorption. Curr. Drug Metab. 2010, 11, 730-742.
43. Anderson, C.M.H.; Grenade, D.S.; Boll, M.; Foltz, M.; Wake, K.A.; Kennedy, D.J.; Munck, L.K.; Miyauchi, S.; Taylor, P.M.; Campbell, F.C.; et al. Thwaites, H+/amino acid transporter 1 (PAT1) is the imino acid carrier: An intestinal nutrient/drug transporter in human and rat. Gastroenterology 2004, 127, 1410-1422.
44. Thwaites, D.T.; Anderson, C.M.H. The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. Br. J. Pharmacol. 2011, 164, 1802-1816.
45. Ganapathy, M.E. Ganapathy, Amino acid transporter ATB0, + as a delivery system for drugs and prodrugs. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2005, 5, 357-364.
46. Hatanaka, T.; Haramura, M.; Fei, Y.-J.; Miyauchi, S.; Bridges, C.C.; Ganapathy, P.S.; Smith, S.B.; Ganapathy, V.; Ganapathy, M.E. Transport of amino acid-based prodrugs by the Na+-and Cl-Coupled amino acid transporter ATB0, + and expression of the transporter in tissues amenable for drug delivery. J. Pharmacol. Exp. Ther. 2004, 308, 1138-1147.
47. Qiu, A.; Jansen, M.; Sakaris, A.; Min, S.H.; Chattopadhyay, S.; Tsai, E.; Sandoval, C.; Zhao, R.; Akabas, M.H.; Goldman, I.D. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 127, 917-928.
48. Zhao, R.; Diop-Bove, N.; Visentin, M.; Goldman, I.D. Mechanisms of membrane transport of folates into cells and across epithelia. Ann. Rev. Nutr. 2011, 31, 177-201.
49. Bai, J.P.F.; Amidon, G.L. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: Implication for oral peptide drug delivery. Pharm. Res. 1992, 9, 969-978.
50. Brandsch, M.; Knütter, I.; Bosse-Doenecke, E. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol. 2008, 60, 543-585.
51. Kikuchi, A.; Tomoyasu, T.; Tanaka, M.; Kanamitsu, K.; Sasabe, H.; Maeda, T.; Odomi, M.; Tamai, I. Peptide derivation of poorly absorbable drug allows intestinal absorption via peptide transporter. J. Pharm. Sci. 2009, 98, 1775-1787.
52. Lee, V.H.L.; Chu, C.; Mahlin, E.D.; Basu, S.K.; Ann, D.K.; Bolger, M.B.; Haworth, I.S.; Yeung, A.K.; Wu, S.K.; Hamm-Alvarez, S.; et al. Biopharmaceutics of transmucosal peptide and protein drug administration: Role of transport mechanisms with a focus on the involvement of PepT1. J. Control. Release 1999, 62, 129-140.
53. Yang, B.; Smith, D.E. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab. Dispos. 2013, 41, 608-614.
54. Giacomini, K.; Huang, S.; Tweedie, D.; Benet, L.; Brouwer, K.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.; et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9, 215-236.
55. Martinez, M.N.; Amidon, G.L. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J. Clin. Pharmacol. 2002, 42, 620-643.
56. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55, 425-461.
57. Shugarts, S.; Benet, L. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 2009, 26, 2039-2054.
58. Posada, M.; Smith, D. Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. Pharm. Res.2013, 30, 1017-1025.
59. Yang, B.; Hu, Y.; Smith, D.E. Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice. Drug Metab. Dispos. 2013, 41, 1867-1874.
60. Jappar, D.; Hu, Y.; Smith, D.E. Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and pept1 knockout mice. Drug Metab. Dispos. 2011, 39, 2250-2257.
61. Jappar, D.; Wu, S.-P.; Hu, Y.; Smith, D.E. Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: In situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab. Dispos. 2010, 38, 1740-1746.
62. Aoki, F.Y.; Doucette, K.E. Oseltamivir: A clinical and pharmacological perspective. Expert Opin. Pharmacother. 2001, 2, 1671-1683.
63. Le, Q.M.; Kiso, M.; Someya, K.; Sakai, Y.T.; Nguyen, T.H.; Nguyen, K.H.L.; Pham, N.D.; Ngyen, H.H.; Yamada, S.; Muramoto, Y.; et al. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005, 437, 1108.
64. Cass, L.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 1999, 36, 1-11.
65. Gupta, S.V.; Gupta, D.; Sun, J.; Dahan, A.; Tsume, Y.; Hilfinger, J.; Lee, K.-D.; Amidon, G.L. Enhancing the intestinal membrane permeability of zanamivir: A carrier mediated prodrug approach. Mol. Pharm. 2011, 8, 2358-2367.
66. Miller, J.M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G.L. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol. Pharm. 2010, 7, 1223-1234.
67. Dawood, F.; Jain, S.; Finelli, L.; Shaw, M.; Lindstrom, S.; Garten, R.; Gubareva, L.; Xu, X.; Bridges, C.; Uyeki, T. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009, 360, 2605-2615.
68. Landowski, C.P.; Vig, B.S.; Song, X.; Amidon, G.L. Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol. Cancer Ther. 2005, 4, 659-667.
69. Tsume, Y.; Hilfinger, J.; Amidon, G. Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: A two-tier monolayer in vitro study. Pharm. Res. 2011, 28, 2575-2588.
70. Tsume, Y.; Hilfinger, J.M.; Amidon, G.L. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: Increased transporter affinity and metabolic stability. Mol. Pharm. 2008, 5, 717-727.
71. Tsume, Y.; Vig, B.; Sun, J.; Landowski, C.; Hilfinger, J.; Ramachandran, C.; Amidon, G. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules 2008, 13, 1441-1454.
72. Han, H.-k.; de Vrueh, R.L.A.; Rhie, J.K.; Covitz, K.-M.Y.; Smith, P.L.; Lee, C.-P.; Oh, D.-M.; Sadee, W.; Amidon, G.L. 5'-Amino acid Esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the Intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15, 1154-1159.
73. Li, F.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 2008, 97, 1109-1134.
74. Mittal, S.; Song, X.; Vig, B.S.; Landowski, C.P.; Kim, I.; Hilfinger, J.M.; Amidon, G.L. Prolidase, a potential enzyme target for melanoma: Design of proline-containing dipeptide-like prodrugs. Mol. Pharm. 2005, 2, 37-46.
75. Song, X.; Lorenzi, P.L.; Landowski, C.P.; Vig, B.S.; Hilfinger, J.M.; Amidon, G.L. Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharm. 2005, 2, 157-167.
76. Tsume, Y.; Bermejo, B.B.; Amidon, G. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs. Pharmaceuticals 2014, 7, 169-191.
77. Tsuda, M.; Terada, T.; Irie, M.; Katsura, T.; Niida, A.; Tomita, K.; Fujii, N.; Inui, K.-I. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J. Pharmacol. Exp. Ther. 2006, 318, 455-460.
78. Ezra, A.; Golomb, G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Deliv. Rev. 2000, 42, 175-195.
79. Ezra, A.; Hoffman, A.; Breuer, E.; Alferiev, I.S.; Mönkkönen, J.; el Hanany-Rozen, N.; Weiss, G.; Stepensky, D.; Gati, I.; Cohen, H.; et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem. 2000, 43, 3641-3652.
80. Gupta, D.; Gupta, S.V.; Dahan, A.; Tsume, Y.; Hilfinger, J.; Lee, K.-D.; Amidon, G.L. Increasing oral absorption of polar neuraminidase inhibitors: A prodrug transporter approach applied to oseltamivir analogue. Mol. Pharm. 2013, 10, 512-522.
81. Halestrap, A.; Meredith, D. The SLC16 gene family-From monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflüg. Archiv. Eur. J. Physiol. 2004, 447, 619-628.
82. Cundy, K.C.; Annamalai, T.; Bu, L.; de Vera, J.; Estrela, J.; Luo, W.; Shirsat, P.; Torneros, A.; Yao, F.; Zou, J.; et al. XP13512, a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther. 2004, 311, 324-333.
83. Cundy, K.C.; Sastry, S.; Luo, W.; Zou, J.; Moors, T.L.; Canafax, D.M. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J. Clin. Pharmacol. 2008, 48, 1378-1388.
84. Cundy, K.C.; Branch, R.; Chernov-Rogan, T.; Dias, T.; Estrada, T.; Hold, K.; Koller, K.; Liu, X.; Mann, A.; Panuwat, M.; et al. XP13512, a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther. 2004, 311, 315-323.
85. González, P.M.; Lagos, C.F.; Ward, W.C.; Polli, J.E. Structural requirements of the human sodium-dependent bile acid transporter (hASBT): Role of 3-and 7-OH moieties on binding and translocation of bile acids. Mol. Pharm. 2013, 11, 588-598.
86. Tolle-Sander, S.; Lentz, K.A.; Maeda, D.Y.; Coop, A.; Polli, J.E. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol. Pharm. 2004, 1, 40-48.
87. Rais, R.; Fletcher, S.; Polli, J.E. Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). J. Pharm. Sci. 2011, 100, 1184-1195.
88. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
89. Dahan, A.; Lennernäs, H.; Amidon, G.L. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol. Pharm. 2012, 9, 1847-1851.
90. Dahan, A.; Miller, J.M.; Amidon, G.L. Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs. AAPS J. 2009, 11, 740-746.
91. Dahan, A.; Miller, J.M.; Hilfinger, J.M.; Yamashita, S.; Yu, L.X.; Lennernas, H.; Amidon, G.L.; High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations. Mol. Pharm. 2010, 7, 1827-1834.
92. Fairstein, M.; Swissa, R.; Dahan, A. Regional-dependent intestinal permeability and BCS classification: Elucidation of pH-related complexity in rats using pseudoephedrine. AAPS J. 2013, 15, 589-597.
93. Zur, M.; Gasparini, M.; Wolk, O.; Amidon, G.L.; Dahan, A. The low/high BCS permeability class boundary: Physicochemical comparison of metoprolol and labetalol. Mol. Pharm. 2014, 11, 1707-1714.
94. Dahan, A.; Wolk, O.; Kim, Y.H.; Ramachandran, C.; Crippen, G.M.; Takagi, T.; Bermejo, M.; Amidon, G.L. Purely in silico BCS classification: Science based quality standards for the world's drugs. Mol. Pharm. 2013, 10, 4378-4390.
95. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26.
96. Sun, D.; Yu, L.; Hussain, M.; Wall, D.; Smith, R.; Amidon, G. In vitro testing of drug absorption for drug "developability" assessment: Forming an interface between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Discov. Dev. 2004, 7, 75-85.
97. Patel, M.; Mandava, N.; Gokulgandhi, M.; Pal, D.; Mitra, A. Amino acid prodrugs: An approach to improve the absorption of HIV-1 protease inhibitor, lopinavir. Pharmaceuticals (Basel) 2014, 7, 433-452.
98. Landowski, C.P.; Lorenzi, P.L.; Song, X.; Amidon, G.L. Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J. Pharmacol. Exp. Ther. 2006, 316, 572-580.
99. Liederer, B.M.; Borchardt, R.T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 2006, 95, 1177-1195.
100. Satoh, T.; Hosokawa, M. The mammalian carboxylesterases: From molecules to functions. Ann. Rev. Pharmacol. Toxicol. 1998, 38, 257-288.
101. Weller, S.; Blum, M.; Doucette, M.; Burnette, T.; Cederberg, D.; de Miranda, P.; Smiley, M. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 1993, 54, 595-605.
102. Balimane, P.V.; Tamai, I.; Guo, A.; Nakanishi, T.; Kitada, H.; Leibach, F.H.; Tsuji, A.; Sinko, P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250, 246-251.
103. Burnette, T.C.; de Miranda, P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab. Dispos. 1994, 22, 60-64.
104. De Miranda, P.; Burnette, T.C. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. 1994, 22, 55-59.
105. Soul-Lawton, J.; Seaber, E.; On, N.; Wootton, R.; Rolan, P.; Posner, J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 1995, 39, 2759-2764.
106. Sinko, P.J.; Balimane, P.V. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm. Drug Dispos. 1998, 19, 209-217.
107. Burnette, T.C.; Harrington, J.A.; Reardon, J.E.; Merrill, B.M.; de Miranda, P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J. Biol. Chem. 1995, 270, 15827-15831.
108. Kim, I.; Chu, X.-y.; Kim, S.; Provoda, C.J.; Lee, K.-D.; Amidon, G.L. Identification of a human valacyclovirase. J. Biol. Chem. 2003, 278, 25348-25356.
109. Lai, L.; Xu, Z.; Zhou, J.; Lee, K.-D.; Amidon, G.L. Molecular basis of prodrug activation by human valacyclovirase, an α-amino acid ester hydrolase. J. Biol. Chem. 2008, 283, 9318-9327.
110. Gupta, D.; Gupta, S.V.; Lee, K.-D.; Amidon, G.L. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol. Pharm. 2009, 6, 1604-1611.
111. Kim, I.; Crippen, G.M.; Amidon, G.L. Structure and specificity of a human valacyclovir activating enzyme: A homology model of BPHL. Mol. Pharm. 2004, 1, 434-446.
112. Kim, I.; Song, X.; Vig, B.S.; Mittal, S.; Shin, H.-C.; Lorenzi, P.J.; Amidon, G.L. A novel nucleoside prodrug-activating enzyme: Substrate specificity of biphenyl hydrolase-like protein. Mol. Pharm. 2004, 1, 117-127.
113. Sun, J.; Dahan, A.; Walls, Z.F.; Lai, L.; Lee, K.-D.; Amidon, G.L. Specificity of a prodrug-activating enzyme hVACVase: The leaving group effect. Mol. Pharm. 2010, 7, 2362-2368.
114. Dahan, A.; Hoffman, A. Mode of administration-dependent brain uptake of indomethacin: Sustained systemic input increases brain influx. Drug Metab. Dispos. 2007, 35, 321-324.
115. Dvir, E.; Elman, A.; Simmons, D., Shapiro, I.; Duvdevani, R.; Dahan, A.; Hoffman, A.; Friedman, J.E. DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. CNS Drug Rev. 2007, 13, 260-277.
116. Dvir, E.; Friedman, J.E.; Lee, J.Y.; Koh, J.Y.; Younis, F.; Raz, S.; Shapiro, I.; Hoffman, A.; Dahan, A.; Rosenberg, G.; et al. A novel phospholipid derivative of indomethacin, DP-155, shows superior safety and similar efficacy in reducing brain amyloid β in an Alzheimer's disease model. J. Pharmacol. Exp. Ther. 2006, 318, 1248-1256.
117. Dahan, A.; Hoffman, A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Control. Release 2008, 129, 1-10.
118. Kurz, M.; Scriba, G.K.E. Drug-phospholipid conjugates as potential prodrugs: Synthesis, characterization, and degradation by pancreatic phospholipase A2. Chem. Phys. Lipids 2000, 107, 143-157.
119. Sun, J.; Dahan, A.; Amidon, G.L. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: A double-targeted prodrug approach. J. Med. Chem. 2010, 53, 624-632.
120. Sun, J.; Miller, J.M.; Beig, A.; Rozen, L.; Amidon, G.L.; Dahan, A. Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality. Expert Opin. Drug Metab. Toxicol. 2011, 7, 313-323.
121. Dahan, A.; Amidon, G.L. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharm. 2009, 6, 19-28.
122. Dahan, A.; Sabit, H.; Amidon, G.L. Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab. Dispos. 2009, 37, 2028-2036.
123. Dahan, A.; Amidon, G.L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297, G371-G377.
124. Dahan, A.; Amidon, G.L. MRP2 mediated drug-Drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int. J. Pharm. 2010, 386, 216-220.
125. Dahan, A.; Sabit, H.; Amidon, G. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: Characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009, 11, 205-213.